Date: 2014-07-29
Type of information: Development agreement
Compound: malaria vaccine
Company: ARTES Biotechnology (Germany) Burnet Institute (Australia) PATH Malaria Vaccine Initiative (MVI)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: development
Action mechanism:
Disease: malaria
Details: * On July 29, 2014, ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). The project will use novel technology developed at the Burnet Institute, by Deputy-Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the Metavax® platform). Purified vaccine antigens (Pfs25 and Pfs230) will be produced as virus-like particles (VLPs, a type of nano-particle) for testing in laboratory studies. The VLPs will be taken up by immune cells to prime and prepare the immune system to fight malaria. The project will focus on strategies to produce vaccines that can block the transmission of malaria infection from mosquitoes to people, as part of a program funded by MVI. ARTES is a Germany-based biotechnology company specialized in recombinant protein production, process and vaccine (VLP-based) development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld.
Financial terms:
Latest news:
